Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.

Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS.

Am J Psychiatry. 2003 Aug;160(8):1413-20.

PMID:
12900302
2.

Amisulpride: from animal pharmacology to therapeutic action.

Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S29-36. Review.

PMID:
9218165
3.

Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.

Möller HJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. Review.

PMID:
14642970
4.

Probing targets for antipsychotic drug action with PET and SPET receptor imaging.

Pilowsky LS.

Nucl Med Commun. 2001 Jul;22(7):829-33. Review.

PMID:
11453058
5.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
6.
7.

Mechanism of new antipsychotic medications: occupancy is not just antagonism.

Grunder G, Carlsson A, Wong DF.

Arch Gen Psychiatry. 2003 Oct;60(10):974-7. Review.

PMID:
14557141
9.

Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.

Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K.

J Clin Psychopharmacol. 2013 Oct;33(5):675-81. doi: 10.1097/JCP.0b013e3182983ffa. Review.

PMID:
23948784
10.

Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C.

CNS Drugs. 2006;20(5):389-409. Review.

PMID:
16696579
11.

Amisulpride: a review of its use in the management of schizophrenia.

Curran MP, Perry CM.

Drugs. 2001;61(14):2123-50. Review.

PMID:
11735643
12.

Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.

Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Küfferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brücke T.

World J Biol Psychiatry. 2002 Jul;3(3):133-46. Review.

PMID:
12478878
14.

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S.

Curr Pharm Des. 2009;15(22):2550-9. Review.

15.

Antipsychotic occupancy of dopamine receptors in schizophrenia.

Nord M, Farde L.

CNS Neurosci Ther. 2011 Apr;17(2):97-103. doi: 10.1111/j.1755-5949.2010.00222.x. Epub 2010 Dec 8. Review.

PMID:
21143431
16.
17.
18.

[The next generation of "atypical" antipsychotics: the role of positron emission tomography].

Gründer G, Wong DF.

Fortschr Neurol Psychiatr. 2003 Aug;71(8):415-20. Review. German.

PMID:
12910447
19.

How do the atypical antipsychotics work?

Ananth J, Burgoyne KS, Gadasalli R, Aquino S.

J Psychiatry Neurosci. 2001 Nov;26(5):385-94. Review.

20.

Supplemental Content

Support Center